Last reviewed · How we verify
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JMKX003002 in Single and Multiple Ascending Dose Randomized，Doubled-blind Phase 1 Study in Healthy Subjects
Safety, tolerability, pharmacokinetics, and pharmacodynamics of JMKX003002 in single and multiple ascending dose randomized，doubled-blind phase 1 study in healthy subjects
Details
| Lead sponsor | Jemincare |
|---|---|
| Phase | Phase 1 |
| Status | UNKNOWN |
| Enrolment | 80 |
| Start date | 2023-05-09 |
| Completion | 2024-03 |
Conditions
- Safety and Tolerability
Interventions
- JMKX003002 will be administered orally
- JMKX003002 will be administered orally
- JMKX003002 will be administered orally
- Placebo in Cohorts 1 to 5
- Placebo in 2 Cohorts
Primary outcomes
- Number of the Adverse Events that are related to the single dose treatment — from baseline to Day 11
single dose safety - Number of the Adverse Events that are related to the multiple dose treatment from baseline to Day 18 — from baseline to Day 18
multiple dose safety
Countries
China